임상 종양 차세대 시퀀싱 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global clinical oncology next generation sequencing market size is expected to reach USD 2.29 Billion in 2034 from USD 0.60 Billion in 2025, growing at a CAGR of 15.97% during 2026-2034.The Global Clinical Oncology Next Generation Sequencing Market is witnessing rapid growth due to increasing demand for precision cancer diagnostics. Next generation sequencing (NGS) enables comprehensive genomic profiling of tumors, supporting targeted therapy decisions. Rising cancer prevalence and growing awareness of personalized treatment approaches are driving market expansion worldwide.

Key growth drivers include advancements in sequencing technologies and decreasing sequencing costs. Healthcare providers are increasingly adopting NGS for early detection and monitoring of cancer progression. Expanding clinical research and supportive government funding are further strengthening market growth. Additionally, pharmaceutical companies are utilizing genomic data for drug development and companion diagnostics.

Looking ahead, the market is expected to benefit from integration of AI-driven bioinformatics tools and liquid biopsy applications. Emerging economies improving oncology care infrastructure will present new growth opportunities. Companies are focusing on enhancing accuracy and reducing turnaround times. As precision oncology becomes standard practice, the Global Clinical Oncology Next Generation Sequencing Market is poised for sustained growth.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Technology

• Whole Genome Sequencing
• Whole Exome Sequencing
• Targeted Sequencing & Resequencing

By Workflow

• NGS Pre-Sequencing
• NGS Sequencing
• NGS Data Analysis

By Application

• Screening (Sporadic Cancer, Inherited Cancer)
• Companion Diagnostics
• Other Diagnostics

By End-use

• Hospitals
• Clinics
• Laboratories

COMPANIES PROFILED

• Foundation Medicine, Illumina, Thermo Fisher Scientific, Guardant Health, Tempus AI, Caris Life Sciences, NeoGenomics, QIAGEN, Roche, BGI, Burning Rock Biotech, Geneseeq, Personalis, Natera, Fulgent Genetics, Exact Sciences, Invitae, ArcherDX, Strata Oncology, SOPHiA GENETICS

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Technology
• 4.2. Whole Genome Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Whole Exome Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Targeted Sequencing & Resequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY WORKFLOW 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Workflow
• 5.2. NGS Pre-Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. NGS Sequencing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. NGS Data Analysis Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Screening (Sporadic Cancer, Inherited Cancer) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Companion Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Other Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY END-USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End-use
• 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Technology
  • 8.2.2 By Workflow
  • 8.2.3 By Application
  • 8.2.4 By End-use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Technology
  • 8.3.2 By Workflow
  • 8.3.3 By Application
  • 8.3.4 By End-use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Spain
  • 8.3.10 Russia
  • 8.3.11 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Technology
  • 8.4.2 By Workflow
  • 8.4.3 By Application
  • 8.4.4 By End-use
  • 8.4.5 China
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 India
  • 8.4.9 Australia
  • 8.4.10 South East Asia
  • 8.4.11 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Technology
  • 8.5.2 By Workflow
  • 8.5.3 By Application
  • 8.5.4 By End-use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Technology
  • 8.6.2 By Workflow
  • 8.6.3 By Application
  • 8.6.4 By End-use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Foundation Medicine
  • 10.2.2 Illumina
  • 10.2.3 Thermo Fisher Scientific
  • 10.2.4 Guardant Health
  • 10.2.5 Tempus AI
  • 10.2.6 Caris Life Sciences
  • 10.2.7 NeoGenomics
  • 10.2.8 QIAGEN
  • 10.2.9 Roche
  • 10.2.10 BGI
  • 10.2.11 Burning Rock Biotech
  • 10.2.12 Geneseeq
  • 10.2.13 Personalis
  • 10.2.14 Natera
  • 10.2.15 Fulgent Genetics
  • 10.2.16 Exact Sciences
  • 10.2.17 Invitae
  • 10.2.18 ArcherDX
  • 10.2.19 Strata Oncology
  • 10.2.20 SOPHiA GENETICS